{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:45:54Z","timestamp":1785228354117,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["2025A03J4203"],"award-info":[{"award-number":["2025A03J4203"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203344"],"award-info":[{"award-number":["82203344"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.dld.2026.03.018","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T20:00:34Z","timestamp":1776715234000},"page":"787-793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk factors and rechallenge outcomes in severe immune-mediated hepatotoxicity: Real-world evidence from two high-volume centers in China"],"prefix":"10.1016","volume":"58","author":[{"given":"Li","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9904-7460","authenticated-orcid":false,"given":"Linbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingfeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.dld.2026.03.018_bib0001","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd.2015.35","article-title":"Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations","volume":"15","author":"Hoos","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.dld.2026.03.018_bib0002","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.dld.2026.03.018_bib0003","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2165\/11594010-000000000-00000","article-title":"Ipilimumab: first global approval","volume":"71","author":"Cameron","year":"2011","journal-title":"Drugs"},{"issue":"28","key":"10.1016\/j.dld.2026.03.018_bib0004","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non\u2012small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.dld.2026.03.018_bib0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primer"},{"issue":"11","key":"10.1016\/j.dld.2026.03.018_bib0006","doi-asserted-by":"crossref","first-page":"7129","DOI":"10.3390\/curroncol31110525","article-title":"Risk factors of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in cancer patients: a systematic review and meta-analysis","volume":"31","author":"Jiang","year":"2024","journal-title":"Curr Oncol Tor Ont"},{"issue":"1","key":"10.1016\/j.dld.2026.03.018_bib0007","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/gastro\/goz044","article-title":"Histologic patterns of liver injury induced by anti-PD-1 therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"Gastroenterol Rep"},{"issue":"9","key":"10.1016\/j.dld.2026.03.018_bib0008","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1634\/theoncologist.2018-0174","article-title":"Diagnosis and management of Hepatitis in patients on checkpoint blockade","volume":"23","author":"Reynolds","year":"2018","journal-title":"Oncologist"},{"issue":"17","key":"10.1016\/j.dld.2026.03.018_bib0009","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with Immune checkpoint inhibitor therapy: american Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"36","key":"10.1016\/j.dld.2026.03.018_bib0010","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.dld.2026.03.018_bib0011","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41571-025-01029-7","article-title":"Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer","volume":"22","author":"Tang","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.dld.2026.03.018_bib0012","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.dld.2026.03.018_bib0013","doi-asserted-by":"crossref","DOI":"10.1007\/s12072-025-10783-w","article-title":"Analysis of risk factors for immune checkpoint inhibitor-associated liver injury: a retrospective analysis based on clinical study and real-world data","author":"Wang","year":"2025","journal-title":"Hepatol Int"},{"issue":"6","key":"10.1016\/j.dld.2026.03.018_bib0014","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1007\/s12072-024-10688-0","article-title":"Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics","volume":"18","author":"Zhang","year":"2024","journal-title":"Hepatol Int"},{"issue":"10","key":"10.1016\/j.dld.2026.03.018_bib0015","article-title":"Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: a 10-year real-world retrospective cohort study","volume":"5","author":"Atallah","year":"2023","journal-title":"JHEP Rep Innov Hepatol"},{"key":"10.1016\/j.dld.2026.03.018_bib0016","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3389\/fphar.2019.00853","article-title":"Roussel Uclaf causality assessment method for drug-induced liver injury: present and future","volume":"10","author":"Danan","year":"2019","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.dld.2026.03.018_bib0017","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s13054-019-2663-7","article-title":"The SOFA score-development, utility and challenges of accurate assessment in clinical trials","volume":"23","author":"Lambden","year":"2019","journal-title":"Crit Care Lond Engl"},{"issue":"12","key":"10.1016\/j.dld.2026.03.018_bib0018","article-title":"Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors","volume":"5","author":"Parlati","year":"2023","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"5","key":"10.1016\/j.dld.2026.03.018_bib0019","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00262-021-03082-4","article-title":"Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus","volume":"71","author":"Lin","year":"2022","journal-title":"Cancer Immunol Immunother CII"},{"issue":"2","key":"10.1016\/j.dld.2026.03.018_bib0020","first-page":"126","article-title":"HBV reactivation and clinical resolution in an isolated anti-HBc-positive patient during immune checkpoint inhibition","volume":"5","author":"Baumert","year":"2024","journal-title":"Med N Y N"},{"issue":"6","key":"10.1016\/j.dld.2026.03.018_bib0021","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2014.07.005","article-title":"Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation","volume":"61","author":"Bengsch","year":"2014","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.dld.2026.03.018_bib0022","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.03.018_bib0023","article-title":"Immune-mediated hepatitis induced by immune checkpoint inhibitors: current updates and future perspectives","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.dld.2026.03.018_bib0024","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2023.10.040","article-title":"Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours","volume":"80","author":"Celsa","year":"2024","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.dld.2026.03.018_bib0025","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","article-title":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"72","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.dld.2026.03.018_bib0026","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/apt.18403","article-title":"Hepatic events during Immune checkpoint inhibitor treatment between liver and non-liver malignancies in Hepatitis B endemic areas","volume":"61","author":"Hung","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dld.2026.03.018_bib0027","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.dld.2026.03.018_bib0028","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s40425-019-0604-2","article-title":"Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.dld.2026.03.018_bib0029","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/toxsci\/kfq009","article-title":"Mechanisms of immune-mediated liver injury","volume":"115","author":"Adams","year":"2010","journal-title":"Toxicol Sci Off J Soc Toxicol"},{"issue":"6","key":"10.1016\/j.dld.2026.03.018_bib0030","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.tranon.2015.11.006","article-title":"Lactate dehydrogenase is an important prognostic indicator for hepatocellular carcinoma after partial hepatectomy","volume":"8","author":"Zhang","year":"2015","journal-title":"Transl Oncol"},{"issue":"7","key":"10.1016\/j.dld.2026.03.018_bib0031","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3109\/0284186X.2015.1043026","article-title":"Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies","volume":"54","author":"Petrelli","year":"2015","journal-title":"Acta Oncol Stockh Swed"},{"issue":"1","key":"10.1016\/j.dld.2026.03.018_bib0032","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatol Baltim Md"},{"issue":"6","key":"10.1016\/j.dld.2026.03.018_bib0033","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.03.018_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: a systemic review and meta-analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"issue":"23","key":"10.1016\/j.dld.2026.03.018_bib0035","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1002\/cncr.33165","article-title":"Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis","volume":"126","author":"Li","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.dld.2026.03.018_bib0036","article-title":"Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma","volume":"5","author":"Scheiner","year":"2023","journal-title":"JHEP Rep Innov Hepatol"},{"key":"10.1016\/j.dld.2026.03.018_bib0037","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: management of Immunotherapy- Related Toxicities. NCCN. Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1486. Accessed August 31, 2025."}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826003324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826003324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:29:09Z","timestamp":1783092549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865826003324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1590865826003324"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2026.03.018","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors and rechallenge outcomes in severe immune-mediated hepatotoxicity: Real-world evidence from two high-volume centers in China","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2026.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}